JGC
AVEO

J. Goldman & Co’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

J. Goldman & Co’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-656,161
Closed -$5.4M – 559
2022
Q3 		$5.4M Sell
656,161
-662,260
-50% -$5.09M 0.26% 117
2022
Q2 		$8.65M Buy
1,318,421
+8,455
+0.6% +$41K 0.42% 66
2022
Q1 		$7.32M Buy
1,309,966
+89,208
+7% +$368K 0.33% 89
2021
Q4 		$5.72M Sell
1,220,758
-442,471
-27% -$2.74M 0.32% 92
2021
Q3 		$10.3M Sell
1,663,229
-157,947
-9% -$945K 0.51% 49
2021
Q2 		$12M Buy
+1,821,176
New +$12.6M 0.47% 55

Other funds holding AVEO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

J. Goldman & Co's AVEO Position: Q4 2022 in Review

J. Goldman & Co sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2022, closing a stake of 656,161 shares — an estimated $5.4M sold.

J. Goldman & Co first reported a position in AVEO in Q2 2021 and held it in 6 quarters. The position peaked at $12M in Q2 2021. 110 funds tracked by Wall St. Rank hold AVEO as of Q4 2022.

  • J. Goldman & Co reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • J. Goldman & Co sold 656,161 AVEO Pharmaceuticals, Inc. shares in Q4 2022, an estimated $5.4M.
  • J. Goldman & Co first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2021 and held it in 6 quarters.
  • J. Goldman & Co's AVEO Pharmaceuticals, Inc. position peaked at $12M in Q2 2021.
  • 110 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2022.

Based on J. Goldman & Co's 13F filing for Q4 2022, filed 14 Feb 2023.